-
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Author: Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B.; Ramalingam, Suresh S.; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; Yang, James Chih-Hsin
Journal: TARGETED ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 9-24. DOI: 10.1007/s11523-022-00941-7
-
Distribution of <Emphasis Type="Italic">ALK</Emphasis> Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Author: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang
Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00631-x
-
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
Author: Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai
Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00630-y
-
Clinical Management of Non-Small Cell Lung Cancer with Concomitant <Emphasis Type="Italic">EGFR</Emphasis> Mutations and <Emphasis Type="Italic">ALK</Emphasis> Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
Author: Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han
Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00628-6
-
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
Author: Xiang Chen, JiaXi Yao, Li Liu, WenZhong Zheng, XiaoYi Hu, YanJun Zhu, Hang Wang, JianMing Guo
Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00625-9
-
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
Author: Zhuanglin Li, Mingxue Wang, Xuejing Yao, Wenting Luo, Yaocheng Qu, Deling Yu, Xue Li, Jianmin Fang, Changjiang Huang
Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-018-0616-8
-
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
Author: Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui
Journal: Targeted Oncology, 2018, Vol.13, 757-767, DOI:10.1007/s11523-018-0602-1
-
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Author: Gaofeng Pan, Shaobo Ke, Jinping Zhao
Journal: Targeted Oncology, 2013, Vol.8, 107-116, DOI:10.1007/s11523-013-0272-y
